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Diagnosis and treatment of HBV±HDV infection means for the patient to be able to maintain working 
capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while socie-
ty benefits from eliminating the chances of further transmission of the viruses, and decreasing the 
incidence and overall costs of serious complications. The guidelines outline the treatment algorithms 
that have been in place since 2019, developed at a consensus meeting of physicians involved in 
treating these diseases. The indications of treatment is based upon viral examinations (including 
viral nucleic acid determination) with determinations of disease activity and stage of related liver 
disease (by laboratory tests, pathologic, and/or non-invasive methods, i.e., elastographies or bio-
chemical scores), and excluding contraindications. The first choices of therapy in chronic hepatitis B 
infection includes pegylated interferon for 48 weeks or continuous nucleotide/nucleoside analogue 
(NAs: entecavir or tenofovir). NAs must be continued for at least 12 months after hepatitis B surface 
antigen seroconversion. Some NAs are not available/not routinely used in Hungary. Lamivudine is 
no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. 
Appropriate treatment of patients taking immunosuppressive medications is highly recommend-
ed. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis 
D infection.
KEYWORDS: hepatitis B virus, hepatitis D virus, viral hepatitis, cirrhosis, liver cancer, interferon, pegylated 
interferon, lamivudine, adefovir, entecavir, tenofovir
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Introduction
Hepatitis B virus is a member of the hepadnavirus family 
with a circular DNA genome. Among adult patients, acu-
te HBV infection becomes chronic in <10% of cases. If the 
infection happens during the perinatal period, this rate is 
>90%. Chronic HBV infection usually causes asymptomatic 
infection for decades, during which, the patient can infect 
other people. However it can also cause chronic inflamma-
tion in the liver (CHB) and – by time – severe liver diseases 
(cirrhosis, liver cancer) which reduces the ability to work, 
the quality of life, and also the life expectancy. In additi-
on, treatment of complications requires great cumulative 
costs from the healthcare system. HBV is a direct onco-
gene. Therefore every patient with chronic HBV infection 
has an increased risk of developing liver cancer even if the 
HBV infection doesn’t cause any significant liver disease. 
The estimated seroprevalence of HBV infection (HBsAg+) 
in Hungary is 0,3–0,5%.
A new nomenclature of the five phases of the HBV in-
fection was accepted by the EASL in 2017. Each phase is 
differentiated from the others on the basis of HBeAg sta-
tus, degree of replication (HBV DNA), biochemical activity 
(GPT/ALT), and the inflammation in the tissues of the liver 
(if histology performed) (Table 1).
Hepatitis D (delta) virus contains RNA genome. It’s a defec-
tive virus; its replication depends on the presence of HBV 
infection. Thus, it can infect only patients with HBV or it 
can be concomitant infection. In most cases, HDV infec-
tion causes more severe liver damage and/or faster prog-
ression of an existing disease (leading to cirrhosis) than 
HBV alone. HDV also means a higher risk of liver cancer.
Chronic HBV/HDV infections usually do not cause any sy-
mptoms. However, early diagnosis and treatment of the 
HBV/HDV infection are essential. From the patients’ aspect: 
it helps the patient to maintain their ability to work, imp-
roves the quality of life, helps prevention of cancer, and 
extends the disease-free lifespan. From the aspect of the 
environment of the patient and also the society: it stops 
the transmission of the infection and reduces the costs of 
the healthcare system (because of the prevention of se-
vere liver diseases). In Hungary, gastroenterologists, infec-
tologists and tropical diseases specialists are assigned to 
manage HBV/HDV infections, according to consensus-ba-
sed professional guideline (since 2006), updated annually 
to include new evidences, publications, international re-
commendations, approved labels of drugs and cost-bene-
fit analysis (1, 2, 3, 4, 5). However, IFN-based therapies for 
HBV and HDV (just like therapies for HCV) are only autho-
rized for specialists at designated Hepatitis Centers, under 
the supervision of a Hepatitis Therapy Committee (former: 
Interferon Committee, hereinafter referred to Committee; 
office: H-1092 Budapest Kinizsi u. 22., E-mail: gastroent@
gmail.com, web: www.gastroent.hu). Members of the 
Com mittee are delegated by professional organizations.
This current guideline is an updated version of the pre-
vious from 2017 (1). It was accepted on the 20th of Sept-
ember, 2019. However, the latest financing protocol of 
NEAK (based on a previous professional guideline from 
Key recommendations
A1.  All patients with a high risk (including every patient 
with chronic liver disease) to be screened for HBV 
(HBsAg, anti-HBc). In high risk populations anti-HBs 
serology must also be performed if immunization 
history is incomplete or unknown.
A2.  In case of HBV seronegativity, vaccination against 
HBV is indicated for all patients with chronic liver 
diseases and also for patients with a high risk of HBV 
infection. Vaccination can also be offered to any 
other individuals.
A3.  Re-test of anti-HBs is recommended 1 month after 
the vaccine series for patients with high risk, such 
as healthcare workers (HCW), people who receives 
blood transfusions or on hemodialysis, and family 
members of infected people. If the titer is below 10 
IU/L, vaccination must be repeated. If the titer is abo-
ve 10 IU/L, the patient is to be considered lifelong 
immunized – so neither re-vaccination nor anti-HBs 
follow up are necessary (except before immuno-
suppressive therapy).
A4.  To exclude/confirm HDV infection, an anti-HD test is 
essential for all HBsAg positive patients. For anti-HD 
positive patients, anti-HD-IgM or HDV RNA test is 
necessary. A HDAg test can also be performed. HDAg 
test gives a positive result characteristically in case of 
acute HDV infection. The negative result of the HDAg 
test doesn’t exclude chronic HDV infection (i.e., repli-
cation of HDV)!
A5.  PCR for HBV DNA test is indicated if the HBsAg test is 
positive.
A6.  Unless contraindicated, anti HBV therapy is recom-
mended if HBV DNA is detectable and the activity of 
the disease and/or fibrosis is confirmed by biochemi-
cal, histological, or non-invasive methods. In additi-
on, some other categories of HBV infected patients 
might need therapy.
A7.  In case of acute severe or fulminant hepatitis B, early 
antiviral therapy (NA) is recommended according to 
the regulations for off-label administration.
A8.  The first choice of anti HBV therapy can be IFN/PEG-
IFN or a NA.
A9.  For both cost-effectiveness aspects and protection 
of the patients (side effects, drug resistance), follow 
up of viral kinetics during the therapy and also 
switching to another therapy when it is needed are 
emphasized.
A10. In case of replication of HDV (positive anti-HD IgM 
and/or HDV RNA and/or HDAg) chronic hepatitis D 
must be treated with IFN/PEG-IFN – independently of 
ALT/GPT values and the titer of HBV DNA. Concomi-
tant NA therapy can be also indicated if HBV DNA is 
also detectable.
A11.  For susceptible individuals, vaccination against he-
patitis A is recommended before or during HBV/HDV 
therapy.
A12.  Because of the increased risk of HCC, abdominal 
ultrasound is necessary for all patients with chronic 
HBV every year. For patients with cirrhosis, this 
ultrasound examination must be performed in every 
6 months.
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2010) was accepted in 2010 and published in the official 
publication of Ministry of Health in 2011 (2). Members 
of the Committee were also involved in development of 
this financial protocol.
The aim of this guideline is to update previous recom-
mendations from 2017. In this guideline, references can 
be found only for recommendations that are different 
from the once in the 2017 version or not included in it. 
This guideline doesn’t substitute the directions of the 
regulations of drug labels published by the OGYÉI!
Diagnosis
Confirmation of HBV/HDV infections and related 
liver disease
Confirmation of HBV infection, HBV genotyping
For all patients with liver disease and unknown HBV and/
or HCV status, HBsAg, anti-HBs, anti-HBc (and anti-HCV) 
serologies are recommended (Table 2). HBV vaccination is 
recommended if HBsAg and anti-HBs serologies are negati-
ve. HBsAg negativity and anti-HBc positivity must be docu-
mented in the medical record of the patient, because occult 
HBV infection is of great importance in blood donation and 
might be relevant in certain diseases and therapies.
Detection of HBsAg and/or HBeAg, and/or HBcAg, and/or 
HBV DNA confirms HBV infection. If persists for more than 6 
months, confirms chronic HBV infection. Replication of HBV is 
to be confirmed by quantitative PCR for HBV DNA. It is recom-
mended even if HBsAg and anti-HBs negative, but anti-HBc 
positive, and liver disease is suspected. Therapy-related PCR 
must be performed in laboratories working with ISO quali-
fication and continuously take part in quality control, accor-
ding to the following methodological and quality terms:
•  real-time PCR with properly sensitive tests (qualification: 
CE-IVD),
•  low detection limit of HBV DNA: lower limit of detection 
≤20 IU/mL,
•  linear quantification range of HBV DNA: 20 IU/mL – 108 
IU/mL,
•  PCR results necessary to the treatment decisions must be 
ready in 5 working days after the arrival of the sample to 
the laboratory.
If possible, HBV genotyping is recommended. A and B ge-
notypes of HBV respond better to IFN therapy than other 
genotypes.
Confirmation of HDV infection
All HBsAg positive patients should be screened for anti-
HD. If anti-HD is positive a positive anti HD-IgM and/or 
HDV RNA and/or HDAg confirms active HDV infection. The 
HDAg is characteristically positive in case of acute HDV 
infection. If the HDAg test is negative, it doesn’t exclude 
chronic HDV infection, and replication of HDV!
Table 1. New terminology of phases of chronic HBV infection (3)
New name
HBeAg positive 
chronic HBV 
infection
HBeAg positive 
chronic  
hepatitis B
HBeAg negative 
chronic HBV 
infection
HBeAg negative 
chronic hepati-
tis B
HBsAg negative 
phase of chronic 
HBV infection 
HBsAg titer high
high/ 
intermediate
low intermediate negative
Anti-HBs negative negative negative negative
characteristically 
negative but it can 
also be positive
HBeAg positive positive negative negative negative
HBV DNA load >107 IU/mL 104-107 IU/mL <2×103 IU/mL >2×103 IU/mL
characteristically 
negative;  
cccDNS in the 
nucleus of liver 
cells
GPT/ALT normal elevated normal elevated normal
Liver damage no/minimal
intermediate/ 
severe
no
intermediate/ 
severe
no
Risk of HCC low increased low increased
there is occurs in 
case of cirrhosis
Old name
immune  
tolerance
immunoreactive 
HBeAg positive
CHB
inactive  
carrier
HBeAg  
negative  
CHB
occult HBV  
infection
Note: Possibility of an occult HBV infection (HBsAg negative phase of chronic HBV infection) should be considered in any HBsAg negative but 
anti-HBc positive patient. However, anti-HBc positivity itself does not prove HBV infection!
Abbreviations: HBsAg = HBV surface antigen; ALT/GPT = alanine transaminase; HBeAg = HBV e antigen;  
anti-HBe = antibody to the HBV e antigen; anti-HBs = antibody to the HBV surface antigen; CHB = chronic viral hepatitis B;  
HBV = hepatitis B virus; HCC = hepatocellular carcinoma; DNA = dezoxyribonucleic acid
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Demonstration of HBV/HDV-related chronic liver 
disease (CLD)
In HBV/HDV infected individuals, demonstration of CLD 
includes demonstration of chronic inflammation by ele-
vated aminotransferases for >6 months (primarily GPT/
ALT) and/or by histology (HAI>1) and/or demonstration of 
fibrosis (F≥1) by liver biopsy, and/or by transient elastog-
raphy (FiroScan, liver stiffness ≥6.0 kPa), and/or by any ot-
her elastography or validated non-invasive methods (e.g. 
FibroTest, ELF test, FIB-4-test). If the GPT/ALT is consistently 
elevated for >6 months and the titer of HBV DNA is above 
2.000 IU/mL (2×103 IU/mL), liver biopsy as well as other fib-
rosis assessment methods can be omitted. Possible other 
causes of CLD must be considered and excluded.
Aminotransferases
Elevated GPT/ALT suggests active hepatitis but it may show 
permanently normal results in the immunotolerant phase of 
the infection, and it can also be intermittently normal in some 
HBeAg negative patients. Its long-term follow-up is essential 
for decision on therapy. Based on clinical studies, for patients 
with chronic hepatitis B the upper limit of normal GPT/ALT is 
35 U/L for men and 25 U/L for women. Between these values 
and the (typically higher) normal values of a particular labo-
ratory, results can be interpreted as ’borderline values’. Ele-
vated GPT/ALT three occasions lasting at least for 6 months 
confirms CLD and supports therapy, as well as one elevated 
GPT/ALT before the start of the therapy if HBV/HDV infection 
certainly/presumably persists for more than 6 months.
Liver biopsy
Hepatitis activity index (HAI) > 1 with confirmed HBV in-
fection for at least 6 months and/or fibrosis stage ≥1 on 
histology confirm CHB. In HBV/HDV infected patients liver 
biopsy might be relevant and recommended for differenti-
al diagnosis and demonstration of other liver diseases.
Non-invasive fibrosis assessment. Liver stiffness (LS) ≥6,0 
kPa on transient elastography (FibroScan) and/or a fibrosis 
stage ≥1 with any other validated non-invasive fibrosis as-
sessment method (e.g. other elastographies, FibroTest, ELF 
test, FIB-4-test) also confirm CLD (3, 4, 6, 7).
Treatment initiation
Indications of HBV/HDV therapy
Goals of HBV therapy
The primary aim of the therapy is the seroconversion of 
HBsAg to anti-HBs. If it is not achieved, the alternative aim 
is to reduce (or cease) the replication of HBV. Further, in 
case of HBeAg positivity, the aim is the seroconversion of 
HBeAg to anti-HBe. In this way, we can abolish/limit the 
inflammation in the liver, prevent or slow down progres-
sion, development of cirrhosis and liver failure, and the risk 
of HCC (8, 9, 10).
No cirrhosis
Treatment of non-cirrhotic HBV infected patients are re-
commended – independently of the HBeAg status –, if 
HBV-DNA is ≥2×103 IU/mL (2.000 IU/mL) and ALT is eleva-
ted. If ALT is normal, liver biopsy and/or non-invasive fibro-
sis assessment is necessary and antiviral therapy is indica-
ted if HAI>1 and/or LS ≥6,0 kPa on transient elastography 
(FibroScan), and/or fibrosis stage ≥1 with any other vali-
dated non-invasive fibrosis assessment method (e.g. other 
elastographies, FibroTest, ELF test, FIB-4-test). If the titer of 
HBV DNA is <2×103 IU/mL, and no CLD can be demonstra-
ted (GPT/ALT is normal, neither fibrosis nor active inflam-
mation can be confirmed), therapy is not recommended 
(exceptions are mentioned in the section of special groups 
of patients) (5) – however these patients are to be followed 
for both viremia and liver disease activity.
Table 2. Serological diagnosis of HBV infection; evaluation HBV status and recommendations
Results of HBsAg, anti-HBs and anti-HBc serologies
Result HBsAg: neg  
Anti-HBs: neg  
Anti-HBc: neg
HBsAg: neg  
Anti-HBs: pos  
Anti-HBc: neg
HBsAg: neg  
Anti-HBs: pos/neg 
Anti-HBc: pos 
HBsAg: pos  
Anti-HBs: neg 
Anti-HBc: pos 
HBV status HBV receptive  
(both actual and 
past HBV infections 
can be excluded)
Vaccinated against 
HBV
Unclear HBV status; 
may have recovered 
from HBV infection, or 
occult HBV infection
HBV infection 
Recommendation Vaccination  
(except if a former 
successful  
vaccination is 
confirmed*)
Anti-HBs >10 IU/L: 
immunised, no 
action required *; 
Anti-HBs  <10 IU/L : 
Booster vaccination, 
repeat anti-HBs titer 
one month later
In case of immuno-
suppression:  
HBV DNA testing;  
if HBV DNA positive: 
occult HBV infection, 
NA therapy
HBeAg, anti-HBe, 
anti-HBc IgM,  
HBV DNA, anti-HD 
testing, then  
according to the 
algorithm in Figure 1.
* Confirmed >10 IU/l anti-HBs titre provides a lifelong immunization – repeat anti-HBs serology or booster vaccination is unnecessary even if 
the titer of anti-HBs decreases or becomes negative by time. 
Abbreviations: HBV = hepatitis B virus; HBsAg = HBV surface antigen; anti-HBs = antibody to the HBV surface antigen;  
anti-HBc = antibody to the HBV core antigen; DNA = dezoxyribonucleic acid; NA = nucleot/side analogue; anti-HD = antibody to the HDV; 
HBeAg = HBV e antigen; anti-HBe = antibody to the HBV e antigen; pos = positive; neg = negative
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Compensated cirrhosis
Any patients with cirrhosis must be treated if HBV DNA is de-
tected – independently of the viral titer and activity. The fol-
lowing results suggest cirrhosis: bridging fibrosis or definitive 
cirrhosis (Knodell F3-F4 or Ishak F4-F5-F6) by histology, and/
or by transient elastography (LS >9.6 kPa) and/or by any other 
validated non-invasive fibrosis assessment method (e.g. any 
other elastography, FibroTest, ELF test, FIB-4-test). Child-Pugh 
score <7 confirms compensated liver disease.
Decompensated cirrhosis
In case of HBsAg positivity, patients with decompensated 
cirrhosis must be treated independently of the titer of HBV 
DNA (even if the titer is negative)! Child-Pugh score ≥7 
confirms decompensated liver disease.
HBV infection and chemotherapy, immunosuppressive or 
biological therapy
PCR for HBV DNA is recommended for patients with positive 
HBsAg and/or anti-HBc if they receive chemotherapy, immu-
nosuppressive or biological therapy, or they’ve undergone 
organ/bone marrow transplantation. If the result is positive, 
the patient must be treated. Therapy might also be recom-
mended for some patients with undetectable HBV DNA.
CHD
IFN/PEG-IFN therapy is recommended if anti-HDV IgM is posi-
tive – even if HBV DNA is not detectable! Patients with Child-
Pugh A cirrhosis must be treated with PEG-IFN in case of 
HDV-Ag or anti-HD-IgM positivity – independently of activity 
and of HBV DNA detectability. If HBV DNA is also detectable, 
concomitant NA therapy can be considered. PEG-IFN is not 
recommended in patients with decompensated cirrhosis.
Additional assessments, measures prior to 
treatment
•  General clinical assessment, in particular, signs of hepa-
tic decompensation (Child-Pugh parameters), signs of 
co-morbidities.
•  HBeAg, anti-HBe serologies.
Figure 1. Algorithm of diagnosis and treatment of chronic hepatitis B with or without hepatitis D
*F stage 1 = fibrosis stage 1 with any validated non-invasive method, or LS ≥ 6,0 kPa by transient elastography.
Abbreviations: HBsAg = HBV surface antigen; HBV = hepatitis B virus; anti-HD = antibody to the HDV; DNA = dezoxyribonucleic acid;  
F0, F1, F2, F3, F4 = stages of fibrosis (Metavir score); HAI = hepatitis activity index; IFN = interferon alpha;  
PEG-IFN = pegylated interferon alpha; ALT/GPT = alanine transaminase; NA = nucleot/side analogue; RNA = ribonucleic acid
Basic examinations
Liver biopsy: HAI >1 
and/or fibrosis stage ³1
F stage ³1* F stage <1*
HBsAg positive,
HBV DNA pos., HDV negative
anti-HD IgM or HDV RNA positive
No decompensated  
cirrhosis
Decompensated  
cirrhosis
Peg-IFN/IFN
HBV DNA >2×103 IU/mL HBV DNA <2×103 IU/mL
NA
ALT elevated ALT normal ALT elevated ALT normal
Peg-IFN/IFN or NA Observation,  
except special cases
Liver biopsy: HAI £1 
and fibrosis stage <1
F stage ³1*F stage <1*
mandatory not mandatory (optional)
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•  HBsAg titer is useful in patients with chronic HBV infec-
tion, primarily for those, to be treated with INF/PEG-INF. 
Recommended, but not mandatory.
•  HAV serology. Vaccination against hepatitis A is recommen-
ded for susceptible patients, before or during the therapy.
•  Anti-HCV, anti-HIV 1-2. If positive, appropriate diagnos-
tics and therapy.
•  Renal functions, TSH.
• Abdominal US (and further imaging if HCC is suspected).
Examinations for co-existing liver diseases: autoimmu-
ne, alcoholic, metabolic liver diseases (including NAFLD, 
NASH).
•  Before starting therapy, the patient must be consulted by 
the attending/treating physician on HBV/HDV infections, 
on activity and stage of liver disease, on goals, modalities 
and conduct of therapy, on treatment options, on prog-
nosis, on preventive measures, and on other relevant is-
sues to obtain a signed informed consent of the patient. 
Figure 1 summarises algorithm of diagnosis and treatment 
of chronic hepatitis B with or without hepatitis D.
Treatment options
In most cases, the first choice of therapy can be either pegy-
lated interferon-alpha (PEG-IFN) or a NA. For treatment de-
cision, patient’s preference is to be taken into account.
Pegylated interferon alpha (PEG-IFN) therapy
First line PEG-IFN therapy is recommended (if no contra-
indication):
•  In HDV co-infected patients (anti-HD IgM, HDV RNA, or 
HDAg positive). Concomitant NA therapy for CHB might 
be considered.
Amongst other options, PEG-IFN therapy is preferred (but 
not mandatory):
•  HBV therapy naive young patients (<40 years),
•  A or B genotypes of HBV,
•  HBeAg negative patients, with:
– GPT/ALT >threefold of the upper limit of normal,
– HBV DNS <2×108 IU/mL,
– HAI ≥2,
Dose of PEG-IFN-alpha-2a: 1×180 mg per week, sc; 1×135 mg 
per week, sc if creatinine clearance is less than 30 mL/min.
Duration: 48 weeks; 72 weeks for anti-HD-IgM positive pa-
tients.
PEG-IFN is contraindicated in patients with decompensa-
ted cirrhosis.
Measuring titer of HBV DNA and serologies during the IFN/
PEG-IFN therapy
HBV DNA is recommended on week 24 of the therapy, 
at the end of therapy, on week 24 and week 48 after the 
therapy. In case of HBeAg positivity, HBeAg and/or anti-
HBe monitoring must be performed with the same sche-
dule. In addition, monitoring of HBsAg titer is also recom-
mended if available. After achieving seroconversion of 
HBeAg to anti-HBe, HBsAg test is recommended in every 
year if HBV DNA cannot be detected. When HBsAg becom-
es negative, anti-HBs serology must be performed.
Evaluation of success of PEG-IFN therapy
•  On-treatment viral response: HBV DNA <2×103 IU/mL at 
week 24 of the therapy
•  Permanent viral response: HBV DNA <2×103IU/mL at 
the end of the therapy, and at week 24 and 48 after 
therapy.
•  Non-adequate on-treatment viral response: not pro-
perly defined. Switching to NA therapy may be consi-
dered if the titer of HBV DNA ≥2×103IU/mL and/or 
the HBV DNA load reduction is <1 log10 at week 24 of 
therapy.
•  Breakthrough: re-occurrence of HBV viraemia or 1 log10 
elevation of the HBV DNS load any time during therapy. 
Switching to NA therapy is recommended.
•  Multiple studies have confirmed that reduction of the 
titre of HBsAg during the PEG-IFN is a positive predictor 
of permanent viral response and also of HBsAg serocon-
version.
Additional monitoring during IFN/PEG-IFN therapy
•  Laboratory monitoring is necessary during the IFN/PEG-
IFN therapy: full blood count, GPT/ALT, GOT/AST, serum 
bilirubin (in every 4 weeks), serum creatinine, blood su-
gar, TSH, and uric acid (in every 12 weeks).
Additional monitoring after IFN/PEG-IFN therapy
•  During (and after) the therapy, abdominal US must be 
performed in annually; every 6 months for patients with 
cirrhosis.
•  After the end of the therapy, liver function and full blood 
count must be monitored at least every 6 months.
•  For HBsAg positive patients and/or if HBV DNA is detec-
table, HBV DNA must be followed annually after the end 
of therapy. If HBV DNA is undetectable, monitoring of 
HBsAg is also recommended. If HBsAg becomes negati-
ve, anti-HBs serology must be performed.
Nucleotide/nucleoside analogue (NA) therapies
If not contraindicated, NA therapy can be chosen 
for the following patients:
•  Amongst other options, a NA can be the first choice of 
therapy in any anti-HD IgM and HDV RNA negative HBV 
infected patients, regardless of HBeAg status.
•  If no-adequate on-treatment viral response to IFN therapy.
•  If there is breakthrough during IFN therapy.
•  If there is no response after the 48-week IFN therapy.
•  If after response to the IFN therapy, there is a relapse.
•  As a second choice of therapy in case of drug resistance 
(in such a case, it can be administered even in combina-
tion).
•  For HBsAg and/or HBV DNA positive patients before, du-
ring and after biological-, immunosuppressive-, or che-
motherapy.
•  HBsAg and/or HBV DNA positive patients who have un-
dergone organ transplantation.
•  Prophylaxis for patients with HBV who undergone organ 
or bone marrow transplantation
•  In any stage of cirrhosis caused by HBV.
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•  In case of any contraindications of IFN.
•  Even for anti-HDV IgM positive patients if the titer of HBV 
DNA is consistently or intermittently >2000 IU/mL and 
IFN therapy is contraindicated or it is not effective.
•  Recommendations for unsuccessful NA therapy or NA 
resistance are listed in Table 3.
Duration of NA therapy
•  NA therapy can be terminated if there is no detectable 
HBV DNA and HBsAg becomes negative (independently 
of anti-HBs!).
•  In case of HBsAg positivity, terminating the NA therapy 
can be considered if ALT/GPT <ULN, there is no cirrhosis, 
progression of fibrosis cannot be detected, regular fol-
low up of the patient after the cessation of therapy can 
be guaranteed, and
– for HBeAg positive patients: HBeAg to anti-HBe sero-
conversion is achieved and HBV DNA cannot be detec-
ted for 12 months of maintenance therapy,
– for HBeAg negative patients: if fibrosis stage is <3, and 
HBV DNA is not detectable for at least 3 years, and the-
re is no (and there wasn’t) any extrahepatic manifesta-
tions of HBV.
HBV DNA and serology follow up during NA therapy
•  HBV DNA test is recommended in every 6 months (every 
three months in cirrhotics) after the initiation of NA thera-
py, and whenever increase of GPT/ALT or other clinical/
laboratory parameter suggests potentially inadequate 
viral response or breakthrough during the therapy.
•  After the first year of ETC, TDF or TAF therapy, annual HBV 
DNA testing is sufficient, if last HBV DNA is not detectab-
le and GPT/ALT is normal.
•  For HBe positive patients on NA therapy, HBeAg and/or 
anti-HBe testing is recommended in every six months. 
•  For HBeAg negative patients on NA therapy, or after 
HBeAg to anti-HBe seroconversion, annual HBsAg tes-
ting is recommended if HBV DNA is undetectable. After 
HBsAg becomes negative, an anti-HBs serology must 
be performed.
Additional follow up during NA therapy
•  During NA therapy, liver functions and blood counts to 
be followed in every 3 months. Significant increase in 
GPT/ALT suggests HBV breakthrough due to a NA resis-
tance-associated substitution/mutation (RAS). RAS tes-
ting is recommended – if available. If RAS is confirmed, 
or RAS testing is not available, switching to another me-
dication is recommended.
•  During TDF/TAF therapy renal functions to be followed 
every month in the first three months of therapy, the-
reafter – if stable – at least in every three months.
•  During (and after) HBV therapy, annual abdominal US is 
necessary to screen for HCC. Patients with cirrhosis are to 
be examined in every 6 months.
Evaluation of on-treatment and post-treatment effi-
cacy of NA therapy
•  Complete viral response: HBV DNA is not detectable.
•  Partial viral response: There is a reduction of HBV DNA 
titer at month 6 of therapy or later on, to >2×103 IU/
mL, but HBV DNA is still detectable. Except the pati-
ent receives ETC, TDF or TAF, switching to another NA 
or a combined NA therapy is recommended, or IFN 
therapy can also be considered. In case of switch to 
INF therapy, ongoing ETC, TDF or TAF therapy to be 
continued.
•  Breakthrough: Re-occurrence of viraemia or increase of 
HBV DNA titer by 1 log10. RAS testing is recommended – 
if available. If RAS is confirmed, or RAS testing is not avai-
lable, switching to another medication is recommended.
•  Permanent viral response: titer of HBV DNA <2.000 
IU/mL during and at least 1 year after the end of NA 
therapy.
Recommendations at the end and after NA therapy
•  At the end of therapy, and thereafter at least every 6 
months (more frequently if unstable): full blood counts, 
liver functions.
•  At the end of therapy, and 6 and 12 months thereaf-
ter: HBV DNA; for HBeAg positive patients, HBeAg and 
anti-HBe. For HBeAg negative patients, HBsAg and an-
ti-HBs.
•  After 48 weeks of post-treatment follow-up: HBV DNA 
annually in the case of HBsAg positivity and/or if HBV 
DNA is detectable. In case of undetectable HBV DNA, 
HBsAg testing is recommended. If HBsAg becomes ne-
gative, anti-HBs testing is recommended.
Table 3. Recommendations for selection of 
entecavir (ETC) or tenofovir alafenamide 
fumarate (TAF) therapy instead of tenofovir 
dipivoxil fumarate (TDF)*
Age over 60 years
Renal impairment or a high risk of renal 
impairment
• eGFR <60 mL/min
• Albuminuria >30 mg/day, proteinuria 
• Hypophosphataemia 
• Active glomerulonephritis
• Hemo-/peritoneal dialysis
• Status after any organ transplantation
• Not (well) controlled high blood pressure 
• Not (well) controlled diabetes mellitus
• Taking other potentially nephrotoxic drugs
Any bone disease or a high risk of bone disease
• Permanent therapy of steroids
•  Permanent therapy of any drugs which decrease 
the bone density
• Pathologic fracture of bones in the patient’s history
*ETC, if the patient has not received LAM or other NA yet. Per label 
dose modification is necessary if eGFR <50 mL/min.
*TAF, if the patient has already received LAM or other NA.
Abbreviations: eGFR = estimated glomerular filtration rate;  
ETC = entecavir; TAF= tenofovir alafenamide fumarate;  
TDF = tenofovir disoproxil fumarate
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•  After discontinuation of HBV therapy: annual abdominal 
US to screen for HCC; every 6 months in patients with 
cirrhosis are to be examined in.
Entecavir (ETC)
•  ETC is one of the most effective types of NAs and there 
is only a very little risk of drug resistance. According to 
the European guideline, it is one of the first drugs of 
choice of NA therapy. Its effectiveness and safety are 
confirmed even for patients with decompensated cirr-
hosis of the liver.
•  ETC is the first choice of NA therapy for patients with 
renal impairment – dose to be adjusted according to 
the label.
•  Because of the risk of developing another resistance, in 
case of LAM resistance, ETC is recommended only if TDF/
TAF are not available or contraindicated.
•  In case of resistance to ETC or if there is detectable HBV 
DNA at week 96 of ETC therapy, switching to TDF or TAF 
is recommended.
•  Dose of ETC: For NA näive patients: 1×0.5 mg daily, per os.; 
1×1,0 mg daily, per os in case of resistance to LAM (not re-
commended if TDF/TAF can be prescribed) and in patients 
with decompensated cirrhosis. For patients with decom-
pensated cirrhosis, TDF or TAF might be more cost-effec-
tive than ETC, thus TDF/TAF is recommended (if there is 
no contraindication). Reduced dose might be appropriate 
for patients with renal impairment, according to the label.
Tenofovir disoproxil fumarate (TDF)
•  TDF is one of the most effective NAs, resistance is not 
known so far. Amongst other options, the European 
HBV guideline recommends it as one of the first drugs of 
choice of NA therapy. 
•  TDF is recommended in case of drug resistance to LAM, 
ADV, or ETC.
•  However, ETC or TAF is recommended instead of TDF for 
patients with bone or kidney diseases or if there is a high 
risk of these diseases (Table 4).
•  Dose of TDF: 1×245 mg daily, per os.
•  During the therapy, kidney function must be followed re-
gularly (every month during the first three months, then 
at least in every 3 months if stable).
Tenofovir alafenamide fumarate (TAF)
•  TAF is an alternative of, and as effective as TDF. Accor-
ding to the clinical studies, TAF affects kidney function 
and bone density in a lower extent than TDF.
•  ETC or TAF is recommended instead of TDF for patients 
with bone or kidney diseases or if there is a high risk of 
these diseases (Table 4).
•  In Child-Pugh B and C stages of cirrhosis, we have no data 
about the effectiveness and safety of TAF, thus it is not re-
commended. In every other case, indications and duration 
of the therapy are the same as of TDF. After it was accep-
ted, – amongst other options – it could be recommended 
as a first-choice therapy (depending on the price).
•  Dose of TAF: 1×25 mg daily, per os.
Adefovir dipivoxil (ADV)
•  Currently not available in Hungary.
•  ADF is less effective than TDF, and the risk of resistance is 
higher. For this reason, ADF is not recommended as first 
line therapy, if other options are available (particularly 
not as monotherapy).
•  Upon TDF and TAF are contraindicated or not avai-
lable, ADV+LAM combination therapy is recommen-
ded in case of LAM resistance. However, switching to 
TDF or TAF is more effective in case of  LAM resistant 
HBV. 
•  In case of resistance to ADV, switching to ETC or TDF or 
TAF is recommended. If the viral titer is ≥108 IU/mL, ETC 
is recommended. 
•  Dose of ADV: 1×10 mg daily, per os. For patients with 
renal impairment, the dose to be reduced according to 
the label. 
Lamivudine (LAM)
•  The risk of drug resistance during LAM therapy is high, 
especially if it is administered as monotherapy. Con-
sequently, initiating new LAM therapy for CHB is in-
dicated only if other NAs contraindicated or not avai-
lable.
•  Ongoing LAM therapy can be continued as long as there 
is no advanced liver disease (F<3), and HBV DNA is <20 
IU/mL.
•  Preventive LAM therapy can also be considered during 
and after biological-, immunosuppressive-, or chemo-
therapy for HBV DNA and HBsAg negative, anti-HBc po-
sitive patients with no advanced liver disease (F<3) if 
expected duration on LAM therapy is not longer than 
1 year.
•  For patients with cirrhosis, LAM monotherapy is contra-
indicated.
•  HBV DNA titer ≥20 IU/mL during LAM therapy suggests 
LAM resistance. Switching to TDF or TAF, or – if TDF or TAF 
is contraindicated or not available – combination of LAM 
with ADV is recommended. ETC therapy carries a higher 
risk of resistance in case of LAM resistance.
•  Dose of LAM: 1×100 mg daily, per os. For patients with 
renal impairment, dose reduction or switching to ETC 
(monotherapy) is recommended, depending on the 
eGFR.
Table 4. Recommendations for second 
and third line therapies if NA resistance is 
confirmed or suspected
Initial NA(s) Second line NA Third line NA(s)
Lamivudine tenofovir*
Adefovir entecavir tenofovir*
Entecavir tenofovir*
Multiple NAs tenofovir* tenofovir* 
+ entecavir
* tenofovir disoproxil fumarate or tenofovir alafenamide fumarate 
(see Table 3.)
Abbreviation: NA = nucleot/side analogue
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NA plus PEG-IFN add-on therapy (11)
•  Add-on NA+PEG-IFN therapy can be chosen for HBeAg 
positive or HBeAg negative patients with CHB if HBeAg 
or HBsAg seroconversion was not achieved after at least 
one-year of NA monotherapy, respectively.
•  Dose: same as for monotherpies.
•  Recommended duration: 48 weeks. Thereafter, continua-
tion of NA therapy is recommended as long as for NA 
monotherapy.
•  Lab tests during and after the combined therapy: same 
as for PEG-IFN and NA monotherapies.
Special patient groups
HBeAg positive patients above 30 years
Antiviral therapy is recommended for HBeAg positive pa-
tients if they are older than 30 years and the titer of HBV 
DNA is high (>2×103 IU/mL) even if the value of the GPT/
ALT is normal. For this group, antiviral therapy (IFN/PEG-
IFN, ETC, TDF or TAF) is recommended independently of 
the degree of activity and fibrosis.
Patients with increased complication risk based on 
family history
Regardless of HBeAg status, patients with chronic HBV 
infection and family history of HCC or of cirrhosis and/or 
extrahepatic manifestation, antiviral therapy should be 
considered (IFN/PEG-IFN, ETC, TDF or TAF).
Patients with compensated cirrhosis
For patients with compensated cirrhosis, std-IFN, PEG-IFN 
alpha-2a, ETC, TDF or TAF are recommended because of the 
low risk of drug resistance. NA therapy must be continued 
lifelong. Discontinuation of NA therapy may be considered 
one year after HBeAg to anti-HBe, or – with more confiden-
ce – after HBsAg to anti-HBs seroconversion, if HBV DNA is 
undetectable.
Patients with decompensated cirrhosis
HBsAg positive patients with decompensated cirrhosis 
require lifelong antiviral therapy (independently of de-
tectability or titer of HBV DNA). ETC must be administe-
red in a high dose (1.0 mg per day) while TDF must be 
administered in a normal dose (1×1.25 mg per day). If 
there is no contraindication, TDF is the first choice NA 
therapy or switching to TDF is indicated (based on cost-
effectiveness). TAF might be a better option, especialy-
ly in cases with impaired kidney function, however the 
safety and efficacy of TAF has not been confirmed in 
these patients so far, thus it is not recommended. Dis-
continuation of NA therapy may be considered one year 
after HBeAg to anti-HBe, or – with more confidence – 
after HBsAg to anti-HBs seroconversion, if HBV DNA is 
undetectable.
HBV infected liver transplant recipients
Before the transplantation, each HBsAg positive patient is 
to receive NA therapy (ETC or TDF) in order to reach the 
lowest possible titer or undetectability of HBV DNA by the 
time of transplantation.
After the transplantation, NA therapy seems to be effective 
and safe, and recommended lifelong to prevent recurren-
ce of HBV. HBsAg positive patients at the time of the tran-
splantation are also to receive HBIG therapy.
Patients after liver transplantation from HBsAg  
negative/anti-HBc positive donor
Recommended prophylaxis after the transplantation is 
listed in Table 5.
Solid organ graft recipients transplanted from  
a HBsAg negative/anti-HBc positive donor
Transplantation of a HBsAg negative/anti-HBc positive do-
nor organ to a HBsAg negative/anti-HBc positive or negati-
ve recipient is not contraindicated if the anti-HBs titer ≥10 
IU/mL at both the donor and the recipient. The recipient 
must be on ETC or TDF therapy for at least 6 months after 
transplantation. ETC must be preferred in case of renal im-
pairment or if there is a high risk of it. Regular HBV serolo-
gies (3 and 6 months after transplantation, every 6 months 
thereafter) and HBV DNA PCRs (6 months after transplan-
tation, thereafter annually) are recommended. If there is 
any suspicion of viral reactivation, unscheduled HBV DNA 
testing is recommended.
Patients with solid organ transplantation from 
HBsAg positive donor
Transplantation of a solid organ from a HBsAg positive do-
nor is generally not recommended, but can be acceptable 
in desperate circumstances. In particular, liver transplan-
tation can only be acceptable if there is no relevant liver 
damage in the donor liver by histology.
After the transplantation of any organs, NA prophylaxis 
is mandatory. Administration of HBIG is also necessitated 
if the anti-HBs titer in the recipient is <100 mIU/L. Follow 
up of HBV DNA, HBsAg and anti-HBs is recommended in 
every three months in the first year; thereafter in every 3-6 
month.
Patients with HBV and HIV co-infections
Indication and conduct of HBV therapy is the same as for 
HIV negative patients. In most cases, simultaneous de 
novo therapy of HIV and HBV is recommended (TDF, emtri-
citabine, and a third anti-HIV medication).
Table 5. Recommended prophylaxis after the 
transplantation
Recipient Prophylaxis
HBsAg pos HBIG + entecavir
Anti-HBs pos and anti-HBc pos not necessary
Anti-HBs neg and anti-HBc pos entecavir
Anti-HBs pos and anti-HBc neg 
(successfully vaccinated)
entecavir
Anti-HBs neg and anti-HBc neg (näiv) entecavir
HBIG = HBV immunoglobulin; HBsAg = HBV surface antigen;  
anti-HBc = antibody to the HBV core antigen;  
anti-HBs = antibody to the HBV surface antigen
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If HBV therapy is initiated prior to HIV therapy, ADV or telbi-
vudine should be chosen because they have no confirmed 
effect on HIV virus. LAM, ETC or TDF monotherapy for HBV 
is contraindicated without concomitant therapy for HIV in 
co-infected patients, because as monotherapy they may 
induce HIV viral resistance due to their anti-HIV activity.
Patients with HBV and HCV co-infections
The titer of HBV DNA is usually low or undetectable in HCV 
co-infected patients. HCV co-infected patients can be trea-
ted for HBV with NAs, according to the guidelines for HBV 
mono-infection. Furthermore, reactivation of HBV may oc-
cur during or after the DAA therapy of HCV; if it occurs, NA 
therapy is to be initiated.
HCV can also be treated in HBV co-infected patients accor-
ding to the guidelines for HCV mono-infection. Efficacy is 
the same as for HCV mono-infected patients. HBsAg, an-
ti-HBs and anti-HBc serologies are necessary before DAA 
therapy. HBsAg positive patients should receive NA thera-
py at the same time, because of the HBV infection. This NA 
therapy must be continued at least 24 weeks after the end 
of the therapy of HCV.
HBsAg negative but anti-HBc positive patients require 
strict follow up during HCV therapy: ALT/GPT in every 
month during the therapy and 1, 3, and 6 months the-
reafter. If the HCV RNA is negative but ALT/GPT is not nor-
malized or rises during or after HCV therapy, HBsAg and 
HBV DNA testing are recommended. Co-administration of 
NA therapy is recommended if HBV flare is confirmed or 
suspected!
Drug-drug interactions of may occur during simultaneous 
therapy of HBV and HCV (Table 6).
Patients with chronic hepatitis D co-infection
IFN/PEG-IFN is the only evidence-based therapy for HDV 
infection. Duration of the therapy is one and a half year; in 
case of a relapse, the therapy should be repeated.
NAs don’t have any effect on the replication of the HDV 
but co-administration of a NA can be recommended if HBV 
DNA is >2×103 IU/mL consistently or intermittently or ot-
her indications of HBV treatment mandate.
After a successful PEG-IFN therapy of chronic hepatitis D 
(IgM anti-HD and/or HDV RNA negative), therapy must be 
continued as for chronic HBV infection.
Patients with fulminant or progressing severe acute 
hepatitis B
NA therapy may be beneficial. Some publications report be-
nefit of LAM therapy, but this is not properly proved in rando-
mized clinical trials yet. ETC, TDF, TAF have excellent anti-HBV 
potential and low risk of viral resistance should be preferred. 
Optimal duration of the therapy is unknown, but continuati-
on as long as in case of CHB is reasonable and recommended. 
Differentiation of real severe acute hepatitis B and from a 
relapse of CHB can be difficult. Liver biopsy might be ne-
cessary. In both cases, NA is the therapy.
HBV infected children
The effectiveness and safety of IFN, LAM, ADV, and enteca-
vir are confirmed for children above 2 years of age.
HBV infected healthcare workers (HCWs)
For HBsAg and HBV DNA positive HCWs, IFN/PEG-IFN, ETC, 
TDF or TAF is recommended.
HBV infected women who plan pregnancy
No advanced fibrosis (F≤2)
Anti-HBV therapy with a 48 week IFN/PEG-IFN prior to 
pregnancy may be considered with a 6 months post-tre-
atment interval before pregnancy. Alternatively, therapy 
of HBV should be postponed after delivery. Proper contra-
ception is mandatory during IFN/PEG-IFN therapy.
Compensated, but advanced liver disease (F3 or F4 fibrosis)
A 48 week IFN/PEG-IFN therapy with a 6 months post-
treatment interval before pregnancy is recommen-
ded for HBV infected women with advanced fibrosis 
Table 6. Potential interactions of recommended NAs and DAAs during concomitant treatment of 
HBV and HCV
NA Entecavir Tenofovir*
HCV therapy (available currently in Hungary)
Elbasvir+gazoprevir 
OBV/PTV/r+DSV 
Glecaprevir+pibrentasvir 
Ledipasvir+sofosbuvir Level of tenofovir* can be elevated 
in the blood. Side effects of tenofo-
vir* must be strictly monitored.
Velpatasvir+sofosbuvir 
Sofosbuvir+velpatasvir+voxilaprevir
* tenofovir disoproxil fumarate or tenofovir alafenamide fumarate  
Green: Clinically significant interactions of drugs are not expected.  
Orange: Clinically significant interactions of drugs may occur– but co-administration with close monitoring for interactions is possible if no 
better option is available.  
Red: These drugs are not to be co-administered because the high risk of a clinically significant interactions (does not occur in these cases).  
Source: http://www.hep-druginteractions.org/checker
Abbreviations: HBV = hepatitis B virus; HCV = hepatitis C virus; DAA = direct acting antiviral agents; NA = nucleot/side analogue;  
OBV/PTV/r+DSV = ombitasvir/paritaprevir/ritonavir/dasabuvir
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but compensated liver disease. Proper contraception 
is mandatory during IFN/PEG-IFN therapy. If IFN/PEG-
IFN therapy is ineffective or contraindicated, tenofovir 
therapy to be initiated and to be continued during and 
after the pregnancy (as long as for CHB treatment), af-
ter detailed counseling with the patient (and family) on 
potential risks and benefits of this therapy during preg-
nancy (15).
Decompensated liver disease
Childbearing potential is low, pregnancy carries high 
maternal and fetal risks, INF/PEG-IFN is contraindicated, 
NAs are either contraindicated or not recommended in 
first two trimesters of pregnancy. For this reasons, preg-
nancy is not recommended for HBV infected women 
with decompensated liver disease. TDF (or ETC) therapy 
is to be initiated, and liver transplantation is to be consi-
dered.
HBV infected pregnant women (12, 13)
According to the FDA, LAM, ADV, and ETC classified into 
pregnancy risk category C, telbivudine and TDF into cate-
gory B. IFN/PEG-IFN is contraindicated.
Recommendations for initiating new HBV therapy are 
identical as for HBV infected women who plan pregnancy.
Continuation or discontinuation of an ongoing HBV thera-
py is to be re-considered and to be counseled with a wo-
man who becomes unexpectedly pregnant. TDF therapy 
may be continued, while IFN/PEG-IFN, LAM, ADV, or ETC 
therapy should be switched to TDF (mandatory in fibrosis 
stage F3 or F4).
To prevent perinatal transmission, in all pregnant women 
with HBV DNA >2x105 IU/ml or HBsAg >1×104 IU/ml, TDF 
prophylaxis should start at week 24–28 of gestation and 
continue for up to 12 weeks after delivery.
HBsAg positive mothers are to be strictly followed after 
delivery, because of the risk of acute flare of HBV hepatitis 
(even if the HBV infection did not require treatment previ-
ously).
Newborns of HBV infected mother
Passive and active immunization of newborn of a HBV in-
fected mother (HBsAg and/or HBV DNA positive) is man-
datory in the perinatal period (within 12 hours after birth). 
However, even with passive and active immunization, the 
risk of the vertical transmission remains still high (>10%) if 
viral load of mother is high in the prenatal period. To dec-
reases the viral load and make active plus passive immu-
nization more effective, from week 24-28 of gestation TDF 
therapy is recommended for pregnant women with HBV 
DNA >2×105 IU/ml or HBsAg >1×104 IU/ml (13).
Breast feeding is NOT contraindicated, neither for HBsAg 
positive untreated women nor during TDF therapy! Con-
centration of TDF in breast milk is relatively low.
Patients who receive chemotherapy, immunosupp-
ressive or biological therapy, bone marrow or stem 
cell transplantation (together: interventions)
For patients with either inactive HBV infection (HBsAg 
positive, no liver damage, no sign of hepatitis) or occult 
HBV infection (HBsAg negative, anti-HBc positive, no liver 
damage, no sign of hepatitis) receiving any of such thera-
pies carries a severe risk of reactivation of HBV infection, 
including fulminant hepatitis. Therefore, HBsAg, anti-HBs 
and anti-HBc are to be screened prior to any of these in-
terventions. If any of the results is positive, hepatology 
consultation is recommended. Furthermore, non-immune 
(seronegative) patients should be actively immunized aga-
inst hepatitis B.
Table 7. Risks of reactivation of HBV in case of various immunosuppressive and biological 
therapies
Risk of HBV reactivation High (>10%) Intermediate (1-10%) Low (<1%)
Anti-HBc positive and
HBsAg 
pos.
HBsAg 
neg.
HBsAg 
pos.
HBsAg 
neg.
HBsAg 
pos.
HBsAg 
neg.
Anti-CD20 X X
Anthracyclin derivates X X
High or intermediate doses of oral  
steroid for ≥4 weeks X X
Anti-TNF-a X X
Other inhibitors of cytokines or integrins X X
Tyrosine kinase inhibitors X X
Small dose of oral steroid for ≥4 weeks X X
Azathioprine, methotrexate X X
Intra-articular teroids X X
Oral steroid for <1 week X X
High dose of steroid: >20 mg/day prednisone or equivalent.
Intermediate dose of steroid: >10 mg/day to ≤20 mg/day prednisone or equivalent.
Small dose of steroid: ≤10 mg/day prednisone or equivalent.
Abbreviations: HBsAg = HBV surface antigen; anti-HBc = antibody to the HBV core antigen; HBV = hepatitis B virus;  
Anti-CD20 = monoclonal antibody to CD20; anti-TNF-a = antibody to tumor necrosis factor alpha
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Regardless of HBsAg status, PCR for HBV DNA is recommen-
ded for all anti-HBc positive patients. (14) For HBsAg and/or 
HBV DNA positive patients, NA therapy (ETC, TDF or TAF) is to 
be initiated prior to (preferably) or during such interventions, 
and to be continued for at least one year after the completion 
of intervention. In case of rituximab mono- or combination 
therapy, NA prophylaxis should continue for at least one and 
a half years after stopping the intervention, and close mo-
nitoring should continue for an additional year threreafter. 
Anti-HBc positive but HBsAg and HBV DNA negative patients 
are to be strictly followed during and after such interventions: 
monthly GPT/ALT, and anti-HBs titer every 3 months (if previ-
ous anti-HBs titer is above 100 IU/L) or HBV DNA level every 3 
months if anti-HBs is below 100 IU/L.
If regular follow up of HBV DNA is not available or the 
anti-HBs titer is below 100 IU/L, NA prophylaxis is re-
commended for all anti-HBc positive, HBsAg negative 
patients who receive rituximab and/or combination 
chemotherapy because of a malignant hematologic di-
sease (15, 16, 17).
NA prophylaxis is also recommended for anti-HBc positive, 
HBsAg and HBV DNA negative patients who receive bone 
marrow or stem cell transplantation (independently of the 
titer of anti-HBs) (18).
ETC, TDF or TAF is recommended for prophylaxis; LAM can 
only be used if its duration is not longer than one year. 
Duration of prophylactic NA therapy is be consulted bet-
ween the haematologist(s) and hepatologist(s).
In case of HBV reactivation, NA therapy is to be initiated, 
and to be continued for at least one and a half years after 
completion of intervention.
Table 7 and Table 8 show the risks and recommendations 
for patients who receive immunosuppressive or biological 
therapy (19, 20, 21).
Patients on hemodialysis or after kidney 
transplantation
Either a NA or IFN/PEG-IFN therapy can be chosen for 
patients with chronic kidney disease. ETC is the optimal 
therapy for kidney transplanted patients – IFN/PEG-IFN is 
contraindicated.
Patients with extrahepatic manifestations
IFN, PEG-IFN or a NA can be considered for HBsAg positive 
and/or HBV DNA positive patients with HBV-related ext-
rahepatic manifestations. However, IFN/PEG-IFN may be 
even unfavorable, harmful, or contraindicated in certain 
immune-mediated extrahepatic manifestations.
In special cases, NA therapy combined with plasmaphere-
sis may increase effectiveness.
Conclusions
HBV infection can cause severe (even fatal) acute hepatitis, 
and may lead to end stage liver disease as well as to HCC 
(even in patients with otherwise not relevant liver disea-
se). These outcomes and related financial burden can be 
greatly reduced with immunization and screening prog-
rams, and with effective therapies.
The incidence, and – in a smaller extent – the prevalence 
of HBV have been recently reduced in countries with im-
munization programs, including Hungary. Unfortunately, 
prevalence is still significant in non-immunized individuals 
(born before 1986 in Hungary). Extension of immunizati-
on program to yet not included populations – especially 
for those at risk – is at upmost importance, and may prove 
cost-effective from health-economy and societal aspects.
As of therapy, it is considered effective if replication of HBV 
is blocked completely, or reduced to a minimal level. If it is 
Table 8. Recommendations for anti-HBc positive patients who receive biological or 
immunosuppressive therapy
Treatment
HBsAg pos. HBsAg neg. HBsAg and HBV DNA neg.
HBV DNA pos. 
or neg.
HBV DNA  
pos.
anti-HBs:  
<100 IU/L
anti-HBs: 
>100 IU/L
Anti-CD20 or anthracyclin derivates NA NA NA Obs1*
Systemic corticosteroids ≥4 weeks,  
or anti-TNF-alpha, other cytokine, 
integrin, or tyrosine kinase inhibitors
NA NA Obs1 Obs1
Azathioprine, methotrexate NA Obs1 Obs1 Obs1
Intra-articular corticosteroid or high  
dose (> 20 mg/die) of systemic  
corticosteroid <4 weeks
Obs2 Obs2 NAR NAR
Small or intermediate dose (≤20 mg/die) 
of systemic corticosteroid <4 weeks Obs3 Obs3 NAR NAR
NA: initiate ETC or TDF or TAF; Obs1 = ALT/GPT at weeks 2 and 4, thereafter monthly, and HBV DNA titer and/or anti-HBs in every three months; 
Obs2 = ALT/GPT on weeks 2 and 4, thereafter monthly for three months, and HBV DNA at month 3; Obs3 = ALT/GPT at weeks 2 and 4.
* Exception: NA therapy is recommended for onco-haematology patients who receive rituximab in mono- or combination  therapy.
Abbreviations: NA = nucleot/side analogue; ETC = entecavir; TAF= tenofovir alafenamide fumarate; TDF = tenofovir disoproxil fumarate;  
Anti-CD20 = antibody to CD20; anti-TNF-a = antibody to tumor necrosis factor alpha; HBsAg = HBV surface antigen;  
anti-HBc = antibody to the HBV core antigen; anti-HBs = antibody to the HBV surface antigen; HBV = hepatitis B virus;  
DNA = dezoxyribonucleic acid; Obs = observation; NAR = no action required; ALT/GPT = alanine transaminase
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Abbreviations 
 ADV = adefovir
 ALT/GPT = alanine transaminase
 anti-HBc = antibody to the HBV core antigen
 anti-HBe = antibody to the HBV e antigen
 anti-HBs = antibody to the HBV surface antigen
 anti-HD = antibody to the HDV
 AST/GOT = aspartate aminotransferase
 CHB = chronic viral hepatitis B
 CHC = chronic viral hepatitis C
 CHD = chronic viral hepatitis D
 CLD = chronic liver disease
 DNA = dezoxyribonucleic acid
 ETC = entecavir
 F0, F1, F2, F3, F4 = stages of fibrosis  
(Metavir score)
 HAI = hepatitis activity index
 HAV = hepatitis A virus
 HBsAg = HBV surface antigen
 HBeAg = HBV e antigen
 HBV = hepatitis B virus
 HCC = hepatocellular carcinoma
 HCV = hepatitis C virus
 HCW = health care workers
 HDAg = HDV antigen
 HDV = hepatitis D virus
 IFN = interferon alpha
 LAM = lamivudine
 LS = liver stiffness
 NA = nucleot/side analogue
 NEAK = Nemzeti Egészségbiztosítási Alap Kezelő 
(National Health Insurance Fund)
 PCR = polymerase chain reaction
 PEG-IFN = pegylated interferon alpha
 RNA = ribonucleic acid
 stdIFN = standard interferon
 TAF= tenofovir alafenamide fumarate
 TDF = tenofovir disoproxil fumarate
 US = ultrasound examination
 DAA = direct acting antiviral agents
 OGYÉI = Országos Gyógyszerészeti és Élelmezés-
egészségügyi Intézet (National Institute of  
Pharmacy and Nutrition)
achieved, risk of complications is low, work-ability and life-
expectancy are close to non-infected individuals. Effecti-
ve therapies are basically available in Hungary. However, 
complete “cure” of HBV with registered therapies is nowa-
days not possible.
Early recognition and per guideline treatment of HBV in-
fection require organized high-scale screening programs. 
Without such programs, reduction of HBV incidence and 
related mortality goal set by WHO cannot be achieved in 
Hungary by 2030.
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